Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes.

Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, Bartels DB.

BMJ Open. 2014 Jan 27;4(1):e003839. doi: 10.1136/bmjopen-2013-003839.

2.

Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.

Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.

Circulation. 2015 Sep 29;132(13):1252-60. doi: 10.1161/CIRCULATIONAHA.115.015710. Epub 2015 Jul 21.

3.

A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.

Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N.

Br J Clin Pharmacol. 2016 Mar;81(3):569-78. doi: 10.1111/bcp.12807. Epub 2015 Dec 28.

4.

Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.

Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KA, Breithardt G, Hacke W.

Ann Intern Med. 2013 Jun 18;158(12):861-8. doi: 10.7326/0003-4819-158-12-201306180-00003.

PMID:
23778903
5.

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.

JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

PMID:
24595776
6.

Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.

Lee SI, Sayers M, Lip GY, Lane DA.

Int J Clin Pract. 2015 Nov;69(11):1341-8. doi: 10.1111/ijcp.12712. Epub 2015 Aug 3.

PMID:
26234557
7.

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.

Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A.

J Thromb Haemost. 2014 Sep;12(9):1401-12. doi: 10.1111/jth.12638. Epub 2014 Jul 24.

8.

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.

Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB.

Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25.

PMID:
24016506
9.

A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.

Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E.

Thromb Haemost. 2015 Nov 25;114(6):1290-8. doi: 10.1160/TH15-06-0453. Epub 2015 Oct 8.

PMID:
26446456
10.

Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.

Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.

J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73. doi: 10.1016/j.jacc.2013.03.020. Epub 2013 Apr 3.

11.

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.

Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Lip GY.

Eur Heart J. 2014 Jul 21;35(28):1897-906. doi: 10.1093/eurheartj/ehu006. Epub 2014 Feb 9.

12.

Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.

Martinez C, Katholing A, Wallenhorst C, Freedman SB.

Thromb Haemost. 2016 Jan;115(1):31-9. doi: 10.1160/TH15-04-0350. Epub 2015 Aug 6.

PMID:
26246112
13.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
14.

Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT.

Stroke. 2016 Feb;47(2):441-9. doi: 10.1161/STROKEAHA.115.011476. Epub 2016 Jan 5.

15.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.

Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

Curr Med Res Opin. 2014 Jul;30(7):1317-25. doi: 10.1185/03007995.2014.907140. Epub 2014 Apr 2.

PMID:
24650301
16.

Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.

Senoo K, Lip GY.

Stroke. 2015 Nov;46(11):3202-7. doi: 10.1161/STROKEAHA.115.010614. Epub 2015 Oct 13.

17.

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.

BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.

18.

[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].

Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, Bagheri H.

Therapie. 2015 Nov-Dec;70(6):485-92. doi: 10.2515/therapie/2015032. Epub 2015 Jul 29. French.

PMID:
26223162
19.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
20.

Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarin.

Kongnakorn T, Lanitis T, Annemans L, Thijs V, Goethals M, Marbaix S, Wautrecht JC.

Clin Drug Investig. 2015 Feb;35(2):109-19. doi: 10.1007/s40261-014-0253-7.

PMID:
25511639

Supplemental Content

Support Center